Montréal-based MY01, a medical technology company that uses microsensors to aid physicians in diagnosing acute compartment syndrome, has received $12.5 million CAD in Series A funding from a group of three Québec-based investors. The round was led by Investissement Québec, with participation from Desjardins Capital and Fondaction.
MY01 is an EAHN™ company and presented at past OBIO® Investment Summits.